Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (19)

2024

  1. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2018

  1. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

    Oncologist, Vol. 23, Núm. 9, pp. 1092-1102

  2. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

2015

  1. Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Españ

    Revista Espanola de Patologia

  2. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer

    Oncotarget, Vol. 6, Núm. 8, pp. 6151-6159

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

  2. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 103-112

  3. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1

2012

  1. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A National Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)

    Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 338-349

  2. Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia

  3. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2009

  1. Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

    Marine Drugs, Vol. 7, Núm. 1, pp. 57-70

  2. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

    Clinical and Translational Oncology

2007

  1. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 6, Núm. 7, pp. 522-528

2003

  1. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

    Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872

2001

  1. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial

    Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38

1997

  1. Mediastinal non-seminomatous germ cell turnouts (MNSGCT) treated with cisplatin-based combination chemotherapy

    Annals of Oncology, Vol. 8, Núm. 6, pp. 555-559